Novel Bayesian Adaptive Designs and Their Applications in Cancer Clinical Trials

DOI10.1007/978-3-030-42196-0_17MaRDI QIDQ5050425zbMATH OpenOpenAlexFDO

Authors

Publication date 15 November 2022

Published in Emerging Topics in Statistics and Biostatistics (Search for Journal in Brave)

Full work available at URL https://doi.org/10.1007/978-3-030-42196-0_17

zbMATH Keywords

adaptive designadaptive randomizationbasket trialBATTLE trialBayesian adaptive designBayesian methodBayesian optimal intervalbinary endpointbiomarkerBOIN designBOP2 designcalibrationcancer trialclinical trialcontinual reassessment methoddecision makingDirichlet distributiondose escalationdose findingdose-limiting toxicityearly stoppingefficacyefficiencyfrequentistfutilityGBM AGILE trialI-SPY2 trialimmunotherapyinterim analysismaster protocolmaximum tolerated dosemodel-assisted designmolecularly targeted agentmultinomial endpointmultiple outcomesoperating characteristicsoptimal designphase I clinical trialphase II clinical trialplatform trialposterior probabilitypredictive probabilityrandomized trialsequential monitoringsimulationsstatistical inferencetime-to-event endpointtoxicityumbrella trial

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10)

Cites work

• A hierarchical Bayesian design for phase I trials of novel combinations of cancer therapeutic agents
• Bayesian Model Averaging Continual Reassessment Method in Phase I Clinical Trials
• Bayesian Response-Adaptive Designs for Basket Trials
• Bootstrap aggregating continual reassessment method for dose finding in drug-combination trials
• Clinical trials. A methodologic perspective
• Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
• Designed Extension of Studies Based on Conditional Power
• Dose-Finding Based on Efficacy-Toxicity Trade-Offs
• Dose-finding with two agents in phase I oncology trials
• Optimal adaptive designs for binary response trials
• Practical Bayesian Guidelines for Phase IIB Clinical Trials
• Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities
• The Theory of Response‐Adaptive Randomization in Clinical Trials

Cited in

(2)

• Bayesian phase I/II adaptively randomized oncology trials with combined drugs
• Bayesian inference of a queueing system with short- or long-tailed distributions based on Hamiltonian Monte Carlo

This page was built for publication: Novel Bayesian Adaptive Designs and Their Applications in Cancer Clinical Trials

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q5050425)